Placebo News and Research

RSS

Rapid responders in novel behavior treatment for IBS maintain improvement at 3-month follow-up

Nearly one-third of patients with irritable bowel syndrome (IBS) who underwent a novel behavior treatment developed by a University at Buffalo behavioral scientist achieved significant relief within four weeks of beginning treatment.

13 May 2010

Regeneron Pharmaceuticals provides update on REGN727, REGN475 antibody product candidates

Regeneron Pharmaceuticals, Inc. (REGN) provided an update on two antibody product candidates in its pipeline and scheduled its first Investor Day to be held in New York City on July 15, 2010. Both product candidates, REGN727 (SAR236553) and, REGN475 (SAR164877) are being developed with sanofi-aventis under a global, strategic collaboration to discover, develop, and commercialize fully human antibodies.

13 May 2010

Resverlogix' Phase 2 ASSERT trial dosing complete ahead of schedule

Resverlogix is pleased to announce that the Phase 2 ASSERT clinical trial for its lead drug, RVX-208, a small molecule therapy for the treatment of atherosclerosis has now completed dosing. "The completion of dosing for our Phase 2 ASSERT trial, five months ahead of schedule and without any alterations to the dose levels of the three drug receiving cohorts, is another major step forward in the development of this important cardiovascular drug.

13 May 2010

Scientists discover link between offspring lung function and maternal vitamin A supplementation

Vitamin A is critical to maternal health and child survival, yet in most developing countries Vitamin A deficiency is a leading cause of blindness and increased child mortality. The Johns Hopkins Bloomberg School of Public Health has long been a leader in vitamin A research, and scientists at the School recently discovered a link between offspring lung function and maternal vitamin A supplementation.

13 May 2010

$High dose Vitamin D linked to high rate of fractures and falls$

High dose Vitamin D linked to high rate of fractures and falls

Many women have been regularly taking vitamin D supplements in the hope that it is good for their bones. However a new study has shown that high doses of this vitamin can actually increase the number of falls and fractures in older women.

12 May 2010

BELLUS Health records a net loss of $4,193,000 for first-quarter 2010

BELLUS Health Inc. reported today its financial results for the first quarter ended March 31, 2010.

12 May 2010

Capstone Therapeutics to continue to planned 12-month endpoints in AZX100 Phase 2a clinical trials

Capstone Therapeutics announced today it has completed a limited analysis of a subset of data from the second of its two ongoing AZX100 Phase 2a clinical trials in keloid scarring. The clinical trial will continue to its planned 12-month endpoints.

12 May 2010

Patient enrollment completed in Phase 2 clinical trial of orBec for prevention of acute GVHD

Soligenix, Inc., a late-stage biopharmaceutical company, announced today that patient enrollment has been completed in a randomized, double-blind, placebo-controlled Phase 2 clinical trial of orBec for the prevention of acute Graft-versus-Host disease after allogeneic hematopoietic cell transplantation with myeloablative conditioning regimens.

12 May 2010

$Study shows high-dose vitamin D therapy may increase risk of fracture in elderly women$

Study shows high-dose vitamin D therapy may increase risk of fracture in elderly women

Women age 70 years or older who received a single annual high dose of vitamin D had a higher rate of falls and fractures compared to women who received placebo, according to a study in the May 12 issue of JAMA.

12 May 2010

Vaccination of infants with Rotarix reduces rate of rotavirus infection: Researchers

Vaccination of infants with Rotarix or RotaTeq significantly reduces the rate of severe rotavirus diarrhoea, hospitalizations, medical attention due to rotavirus and severe diarrhoea from all causes. The vaccines are not associated with increased numbers of serious adverse events.

12 May 2010

Study confirms Resveratrol's impact on cognitive processes of the brain

The subject of extensive studies across the world, Resveratrol is proving to be a major talking point in the scientific community. And as evidence comes to light of the continuing beneficial effects of this compound, a further study by the University of Northumbria in the UK has confirmed what many scientists already believe to be the case - that Resveratrol could have a significant impact on the cognitive processes of the human brain.

12 May 2010

Pacira Pharmaceuticals receives $11.25M credit facility from GE Capital, Healthcare Financial Services

GE Capital, Healthcare Financial Services today announced it has provided an $11.25 million credit facility to Pacira Pharmaceuticals, Inc. The financing provides working capital, and facilitates advances toward regulatory approval and preparation for commercialization of Pacira's EXPAREL™ program.

12 May 2010

Update on Nymox Pharmaceutical's Phase 3 program for NX-1207

Nymox Pharmaceutical Corporation provided an update today on the Company's Phase 3 program for NX-1207, Nymox's investigational drug for benign prostatic hyperplasia. The most recent Safety Monitoring Committee meeting of April 30, 2010 for the Phase 3 U.S. pivotal trials of NX-1207 indicated no significant safety concerns for the trials to date.

12 May 2010

Phase IIb study of EVP-6124 initiated in patients with Alzheimer's disease

EnVivo Pharmaceuticals today announced the initiation and dosing of patients in a Phase IIb study of its EVP-6124 compound, a selective alpha-7 nicotinic agonist in patients with mild to moderate Alzheimer's disease.

12 May 2010

Transition Therapeutics reports increased revenue in third-quarter 2010

Transition Therapeutics Inc., a product-focused biopharmaceutical company developing therapeutics for disease indications with large markets, today announced its financial results for the quarter ended March 31, 2010.

11 May 2010

Forest, Almirall to present data on aclidinium bromide for COPD and LAS100977 for asthma at ATS conference

Forest Laboratories, Inc. and Almirall, S.A. today announced that they are presenting data from several studies of two investigational inhaled respiratory compounds at the annual American Thoracic Society International Conference taking place in New Orleans May 14-19, 2010. Data on aclidinium bromide, an inhaled muscarinic antagonist, which is in Phase III development for COPD, and LAS100977, a long-acting beta 2-agonist, in Phase II development for asthma, will be presented in 11 separate posters.

11 May 2010

Sucampo presents phase 3 trial results of lubiprostone in non-cancer pain patients with OBD at DDW 2010

Sucampo Pharmaceuticals, Inc. today announced the presentation of results from a phase 3 clinical trial investigating the use of lubiprostone in non-cancer pain patients with Opioid-induced Bowel Dysfunction (OBD). These results were the subject of an oral presentation at the Digestive Disease Week (DDW) 2010 conference in New Orleans, Louisiana, on May 5, 2010.

11 May 2010

Aastrom Biosciences reports third quarter 2010 FY results

Aastrom Biosciences, Inc., the leading developer of autologous cellular therapies for the treatment of severe cardiovascular diseases, today reported financial results for its third fiscal quarter ended March 31, 2010, and also announced progress in its late-stage clinical development programs and corporate operations.

11 May 2010

Harbor BioSciences reports encouraging results from Triolex Phase IIa trials

Harbor Biosciences, a biopharmaceutical company developing novel therapeutics for the treatment of cancer, metabolic and inflammatory diseases, today released an update to its development program for Triolex to treat obesity-induced insulin resistance and type-2 diabetes mellitus (T2DM).

10 May 2010

Lexicon Pharmaceuticals first-quarter revenues down 61%

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease, today updated its drug development progress and reported financial results for the three months ended March 31, 2010.

10 May 2010

Placebo News and Research

Rapid responders in novel behavior treatment for IBS maintain improvement at 3-month follow-up

Regeneron Pharmaceuticals provides update on REGN727, REGN475 antibody product candidates

Resverlogix' Phase 2 ASSERT trial dosing complete ahead of schedule

Scientists discover link between offspring lung function and maternal vitamin A supplementation

High dose Vitamin D linked to high rate of fractures and falls

BELLUS Health records a net loss of $4,193,000 for first-quarter 2010

Capstone Therapeutics to continue to planned 12-month endpoints in AZX100 Phase 2a clinical trials

Patient enrollment completed in Phase 2 clinical trial of orBec for prevention of acute GVHD

Study shows high-dose vitamin D therapy may increase risk of fracture in elderly women

Vaccination of infants with Rotarix reduces rate of rotavirus infection: Researchers

Study confirms Resveratrol's impact on cognitive processes of the brain

Pacira Pharmaceuticals receives $11.25M credit facility from GE Capital, Healthcare Financial Services

Update on Nymox Pharmaceutical's Phase 3 program for NX-1207

Phase IIb study of EVP-6124 initiated in patients with Alzheimer's disease

Transition Therapeutics reports increased revenue in third-quarter 2010

Forest, Almirall to present data on aclidinium bromide for COPD and LAS100977 for asthma at ATS conference

Sucampo presents phase 3 trial results of lubiprostone in non-cancer pain patients with OBD at DDW 2010

Aastrom Biosciences reports third quarter 2010 FY results

Harbor BioSciences reports encouraging results from Triolex Phase IIa trials

Lexicon Pharmaceuticals first-quarter revenues down 61%

Industry Focus eBook - Life Science Microscopy (2nd Edition) eBook

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News